Berberine 用于 小肠细菌过度生长（SIBO）
C 证据 来自小型研究的证据有限，但存在一些积极信号。回顾性研究显示，包含小檗碱的草本抗菌方案对SIBO的疗效与利福昔明相当。前瞻性RCT数据有限。
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dberberine\u0026condition\u003Dsibo';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
结论
回顾性研究显示，包含小檗碱的草本抗菌方案对SIBO的疗效与利福昔明相当。前瞻性RCT数据有限。
Key Study Findings
Meta-Analysis
n=1552
Comparative efficacy of diverse therapeutic regimens for small intestinal bacterial overgrowth: a systematic network meta-analysis.
Dose: None
vs: Multiple comparators (network meta-analysis)
Outcome: SIBO eradication rate
效果: Berberine highest SUCRA
None
研究人群: Adults with SIBO from 30 RCTs
Randomized Controlled Trial
2 weeks
Open-label
Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, …
Dose: 400 mg d
vs: control
Outcome: a negative breath test
效果: None
None
研究人群: Long-term abdominal discomfort and avoiding excessive examination
Key Statistics
2
研究数量
180
受试者
↑
Positive
C
等级
Referenced Papers
Therapeutic advances in …
2025
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
常用剂量
- general:
- 500-1,500 mg/day in divided doses
- siboprotocol:
- 500 mg two to three times daily for 4 weeks (as part of herbal antimicrobial protocol)
- giantimicrobial:
- 500 mg twice daily
上限： Generally well-tolerated up to 1,500 mg/day in divided doses
研究中使用的剂量
| 剂量 | 持续时间 | 效果 | N |
|---|---|---|---|
| None | -- | Positive | 1552 |
| 400 mg d | 2 weeks | Mixed | -- |
最佳服用时间： With meals; divide doses throughout the day (do not take full daily dose at once)
Safety & Side Effects
已报告的副作用
- ⚠ GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common
- ⚠ May cause uterine contractions (contraindicated in pregnancy)
- ⚠ Headache
- ⚠ Skin rash (rare)
已知相互作用
- ● Diabetes medications (berberine significantly lowers blood sugar; risk of hypoglycemia)
- ● Cyclosporine (berberine inhibits CYP3A4, increasing cyclosporine levels)
- ● Anticoagulants (may have additive blood-thinning effects)
- ● Metformin (additive glucose-lowering effect; monitor closely)
- ● Macrolide antibiotics (berberine inhibits CYP3A4)
可耐受最高摄入量： Generally well-tolerated up to 1,500 mg/day in divided doses
在开始服用任何补充剂之前，请务必咨询您的医疗保健提供者。
Frequently Asked Questions
Does Berberine help with 小肠细菌过度生长（SIBO）?
Based on 2 studies with 180 participants, there is limited but promising evidence that Berberine may support 小肠细菌过度生长（SIBO） management. Our evidence grade is C (Some Evidence).
How much Berberine should I take for 小肠细菌过度生长（SIBO）?
Studies have used various dosages. A commonly studied range is 500-1,500 mg/day in divided doses. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Berberine?
Reported side effects may include GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common, May cause uterine contractions (contraindicated in pregnancy), Headache, Skin rash (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Berberine and 小肠细菌过度生长（SIBO）?
We rate the evidence as Grade C (Some Evidence). This rating is based on 2 peer-reviewed studies with 180 total participants. The overall direction of effect is positive.
Related Evidence
其他成分用于 小肠细菌过度生长（SIBO）
References
- [1] Qinlin Zhang et al.. Therap Adv Gastroenterol. 2025. Comparative efficacy of diverse therapeutic regimens for small intestinal bacterial overgrowth: a systematic network meta-analysis. doi:10.1177/17562848251399033 PubMed
- [2] Huaizhu Guo et al.. Front Pharmacol. 2023. Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO … doi:10.3389/fphar.2023.1121435 PubMed
FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。